



02/01
US PTO
1997

02-05-01

A
BOK SEQ

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. C1037/7013(HCL/MAT)

First Named Inventor or Application Identifier

BRATZLER, Robert L.

Express Mail Label No. EL711263015US

Date of Deposit February 2, 2001

J1037/716479 PRO
02/02/01
5479

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents</small>		ADDRESS TO:	Box Patent Application Commissioner for Patents Washington, DC 20231
<p>1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification [Total pages 85] 80 - pages description 1 - pages abstract 4 - pages claims 36 - Total claims</p> <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total sheets _____] <input type="checkbox"/> Informal <input type="checkbox"/> Formal [Total drawings _____]</p> <p>4. <input type="checkbox"/> Oath or Declaration [Total pages] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> <i>[Note Box 5 below]</i></p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>		<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p>	
ACCOMPANYING APPLICATION PARTS			
<p>8. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s)</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney</p> <p>10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i></p> <p>11. <input type="checkbox"/> Information Disclosure Statement PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. Other: This application claims priority under Title 35 §119(e), of United States Provisional Application No. 60/179,991, filed February 3, 2000, entitled IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE TREATMENT OF ASTHMA AND ALLERGY, the entire contents of which are incorporated herein by reference.</p>			
<p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: _____</p> <p><input type="checkbox"/> Cancel in this application original claims of the prior application before calculating the filing fee.</p> <p><input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a <input type="checkbox"/> continuation <input type="checkbox"/> divisional of application serial no. , filed , entitled , and now .</p>			

18. CORRESPONDENCE ADDRESS

Correspondence address below					
ATTORNEY'S NAME	Helen C. Lockhart, Reg. No. 39,248				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Helen C. Lockhart, Reg. No. 39,248
SIGNATURE	
DATE	February 2, 2001

**Express Mail No. EL711263015US
Date of Mailing: February 2, 2001
Attorney Docket No: C1037/7013 (HCL/MAT)**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert L. Bratzler et al.
Serial No.: Not Yet Assigned
Filed: Herewith
Entitled: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE TREATMENT OF
ASTHMA AND ALLERGY

Box Patent Application
Commissioner for Patents
Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith a paper copy of the Sequence Listing and a computer readable diskette. Applicants' attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,



Helen C. Lockhart
Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Docket No. C1037/7013 (HCL/MAT)

Date: February 2, 2001

X02/02/01